Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2024-07-23 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司向不特定对象发行可转换公司债券募集说明书
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to a "Prospectus" or "Offering Circular" for the issuance of convertible corporate bonds to unspecified investors. It contains detailed information about the bond issuance, including credit ratings, risk factors, dividend policies, management commitments, and extensive financial and operational disclosures. The document is lengthy (15,000 characters) and includes detailed financial and management analysis related to the bond issuance. This type of document is a capital raising disclosure related to financing activities. It is not an annual report, earnings release, or management discussion, nor is it a regulatory filing or announcement of a report. It is a detailed financing update document describing the terms, risks, and use of proceeds of a convertible bond issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-07-23 Chinese
奥锐特药业股份有限公司2024年半年度业绩预增公告
Earnings Release Classification · 95% confidence The document is a performance forecast announcement for the first half of 2024, indicating expected net profit increases compared to the previous year. It explicitly states that the data is preliminary, unaudited, and that the final accurate financial data will be disclosed in the formal 2024 half-year report. The document length is short (1390 characters), and it does not contain actual financial statements or detailed financial analysis, only a forecast and summary. Therefore, it is not an Interim/Quarterly Report (IR) but rather an earnings performance forecast announcement. This type of document fits best under Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results highlights. H1 2024
2024-07-09 Chinese
奥锐特药业股份有限公司关于全资子公司完成工商变更登记并换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of a business registration change and issuance of a new business license for a wholly-owned subsidiary. It contains no financial data, no report or presentation, and no voting or management changes. It is a regulatory announcement about corporate administrative changes. The document length is short (705 characters), and it is not a report or financial filing but a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS).
2024-07-04 Chinese
奥锐特药业股份有限公司关于向不特定对象发行可转换公司债券申请获得中国证券监督管理委员会同意注册批复的公告
Capital/Financing Update Classification · 100% confidence The document is an official announcement from 奥锐特药业股份有限公司 regarding the approval from the China Securities Regulatory Commission (CSRC) for the company's application to issue convertible bonds to unspecified investors. It includes details about the registration approval, conditions, and validity period. The content focuses on a capital raising activity through convertible bonds issuance, which is a financing update. The document is short (585 characters) and is not a full financial report but an announcement of a financing event. Therefore, it fits best under the category 'Capital/Financing Update' (CAP).
2024-06-24 Chinese
奥锐特药业股份有限公司2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2023 annual dividend distribution by 奥锐特药业股份有限公司. It details the dividend per share, relevant dates for dividend distribution, tax withholding policies, and shareholder meeting approval. The document is focused on dividend payment details rather than the full annual report or financial statements. It is not a report itself but an announcement of dividend amount and payment details. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is short and specific to dividend distribution, confirming this classification.
2024-05-29 Chinese
奥锐特药业股份有限公司2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2023 Annual General Meeting (AGM) of 奥锐特药业股份有限公司, including voting results on various agenda items such as the annual report, board work report, financial statements, profit distribution, auditor appointment, and remuneration plans. It includes attendance details, voting percentages, and legal witness statements confirming the validity of the meeting and resolutions. The document is not the annual report itself but the official announcement of the AGM resolutions and voting outcomes. The document length is 3488 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-05-20 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.